Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pohar

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Cancer Research|April 18, 2001
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2M Esteller, C Cordon-Cardo, P G Corn, et al.
Urologic Oncology|April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trialSiamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
European Urology Oncology|October 23, 2018
Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer PatientsStephen B Williams, Ashish M Kamat, Karim Chamie, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
Nature Reviews. Urology|September 24, 2014
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USASiamak Daneshmand, Anne K Schuckman, Bernard H Bochner, et al.
The Journal of Clinical Investigation|January 31, 2017
Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinomaLindsey N Kent, Sooin Bae, Shih-Yin Tsai, et al.
The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.
Journal for Immunotherapy of Cancer|October 3, 2025
T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancerJohanna M Schafer, No-Joon Song, Tong Xiao, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Kidney cancer. Clinical practice guidelinesRobert J Motzer, Michael A Carducci, Mayer Fishman, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Cancer Research|April 18, 2001
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2M Esteller, C Cordon-Cardo, P G Corn, et al.
Urologic Oncology|April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trialSiamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
European Urology Oncology|October 23, 2018
Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer PatientsStephen B Williams, Ashish M Kamat, Karim Chamie, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
Nature Reviews. Urology|September 24, 2014
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USASiamak Daneshmand, Anne K Schuckman, Bernard H Bochner, et al.
The Journal of Clinical Investigation|January 31, 2017
Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinomaLindsey N Kent, Sooin Bae, Shih-Yin Tsai, et al.
The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.
Journal for Immunotherapy of Cancer|October 3, 2025
T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancerJohanna M Schafer, No-Joon Song, Tong Xiao, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Kidney cancer. Clinical practice guidelinesRobert J Motzer, Michael A Carducci, Mayer Fishman, et al.
Pageof 7